Navigation Links
Tamiflu drug approved in Europe for children’

Tamiflu, anti-influenza drug, which is produced by Roche Pharmaceuticals, has been approved by the European authorities to be used as // an anti-flu prevention drug in children’s between the ages of 1 to 12 years. Roche Pharmaceuticals and diagnostics is a leading healthcare company situated in Switzerland and are manufacturers of Tamiflu drug.

Tamiflu drug is found to be an effective influenza virus drug, which inhibits the replication of the virus by blocking the enzyme action. Tamiflu drug is found to be effective in treating younger adults and adults and a clinical study conducted to prove the efficacy of Tamiflu drug in treating children’s aged between 1 and 12 years was found to be effective in controlling and treating patients with influenza virus, treating children’s below 12 years of age is very important as treating the old as they are more vulnerable and susceptible to the virus infection and spread due to a decreased host immune system.

Roche the manufacturers of Tamiflu drug is collaborating with WHO in distribution and stocking of Tamiflu drugs worldwide. Even WHO as asked all countries to stock Tamiflu drug, which as showed very good results in treating influenza virus infection. Though the requirement of countries for Tamiflu drug is very high, Roche is working hard to supply all the countries with its drug Tamiflu to prevent a pandemic of bird flu infection.

'"/>




Page: 1

Related medicine news :

1. Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid
2. India To Procure 1 Million Doses Of Tamiflu
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. US Regulator Sees No Link Between Tamiflu And Japan Deaths
5. Roche confirms Tamiflu production talks in US
6. Dosage Of Tamiflu Sought To Be Increased
7. Tamiflu Fails To Save Two Lives
8. Christmas trees to yield key Tamiflu ingredient
9. India to produce Tamiflu generic ‘Oseltamivir
10. A success for the Indian pharmacy: gets licence to manufacture Tamiflu
11. Hyderabad Firm To Manufacture Tamiflu In India
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million people ... from the epidemic of diabetes. 1 However, nearly ... elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... complications, including cardiovascular events. If left untreated, hyperglycemia can ... eye disease or blindness. 3 As ...
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... , Dec. 6, 2016  Blueprint Medicines Corporation ... and developing targeted kinase medicines for patients with genomically ... underwritten public offering of $125,000,000 million in shares of ... grant the underwriters a 30-day option to purchase up ... its common stock in connection with the public offering. ...
Breaking Medicine Technology: